Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU Cohort Study
The Journal of Rheumatology, 06/06/2011
Ivorra JAR et al. – Previously reported results of bosentan efficacy in DU management are reproducible in clinical practice. This efficacy is maintained in the longterm followup. Bosentan treatment was well tolerated and adverse events were comparable with those observed in previous reports.
Multicenter, noninterventional retrospective cohort study
Data collected retrospectively from patients with DU, with or without PAH, who were initiating bosentan therapy in 2003 (n = 26) or 2004 (n = 41) and followed until May 2005
Data were obtained from centers prescribing bosentan
Relevant measures included number of DU, occurrence of new DU, overall DU clinical status (improved, stabilized, worsened), and bosentan-associated AEs
67 patients with SSc and DU or other ulcers included
PAH was also present in 12 patients (18%)
At start of bosentan treatment, median number of DU per patient was 3.0
Median change in number of DU -3.6 and -5.0 at 12 and 24 months
68% of patients did not develop any new DU at 12 months
DU clinical status reported at 12 months for 22 patients: 18 patients (81.8%) improved and 4 (18.2%) stabilized
Median treatment duration 13.0 months
Main AE was increase of aminotransferase, observed in 5 patients (7%), leading to discontinuation of treatment in 3 patients (4.4%)
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.